Table 2. Upfront treatment regimens in... | American Society of Hematology

Table 2.

Upfront treatment regimens in PCNSL

Study	Regimen	ORR, %	2-y PFS, %	Treatment-related deaths, %
DeAngelis et al, 2002²⁴	MVP+WBRT+IT MTX	94	50	8
Morris et al, 2013³⁵	R-MVP+Ara-C+low-dose WBRT	95	77	6
Ferreri et al, 2009²⁶	MA+WBRT	69	38	8
Thiel et al, 2010²⁹	MTX/WBRT vs MTX	53 (in all patients)	43.5 vs 30.7	5
Rubenstein et al, 2013³⁶	MT-R	66	57	2
Omuro et al, 2015³⁹	R-MVP + ASCT	96	79	9
Omuro et al, 2015³⁷	MT vs MVP	71 vs 82	39 vs 58	10 vs 6
Ferreri et al, 2016³³	MA vs MARix vs MATRix	40 vs 51 vs 65	36 vs 46 vs 61	6
Bromberg et al, 2019³⁴	R-MBVP vs MBVP	81 vs 75	43 vs 37	2 vs 3

Study	Regimen	ORR, %	2-y PFS, %	Treatment-related deaths, %
DeAngelis et al, 2002²⁴	MVP+WBRT+IT MTX	94	50	8
Morris et al, 2013³⁵	R-MVP+Ara-C+low-dose WBRT	95	77	6
Ferreri et al, 2009²⁶	MA+WBRT	69	38	8
Thiel et al, 2010²⁹	MTX/WBRT vs MTX	53 (in all patients)	43.5 vs 30.7	5
Rubenstein et al, 2013³⁶	MT-R	66	57	2
Omuro et al, 2015³⁹	R-MVP + ASCT	96	79	9
Omuro et al, 2015³⁷	MT vs MVP	71 vs 82	39 vs 58	10 vs 6
Ferreri et al, 2016³³	MA vs MARix vs MATRix	40 vs 51 vs 65	36 vs 46 vs 61	6
Bromberg et al, 2019³⁴	R-MBVP vs MBVP	81 vs 75	43 vs 37	2 vs 3

IT, intrathecal; MA, MTX/cytarabine(Ara-C); MARix, MTX/cytarabine/rituximab; MBVP, MTX/carmustine/teniposide/prednisone; MT, MTX/temozolomide; MT-R, rituximab/MTX/temozolomide; MVP, MTX/vincristine/procarbazine; R-MBVP, rituximab/MTX/carmustine/teniposide/prednisone.

View Large

This Feature Is Available To Subscribers Only